Physician profile
Brent R Moody
NPI 1457448599
$1,022,575.43
in general payments reported to CMS, 2019-2025
14 companies · $149K in 2025
The $149K reported for 2025 was more than what 99% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358K · 2020: $153K · 2021: $180K · 2022: $63K · 2023: $55K · 2024: $63K · 2025: $149K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $147K · Consulting Fee: $74K · Travel and Lodging: $27K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Food and Beverage: $5,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $146,549.35 |
| Consulting Fee | $74,053.00 |
| Travel and Lodging | $26,624.95 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,960.00 |
| Food and Beverage | $5,518.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $365,430.79 | 2019-2023 | Erivedge |
| Regeneron Healthcare Solutions, INC. | $329,705.35 | 2019-2025 | Libtayo |
| Genzyme Corporation | $198,605.74 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $103,412.21 | 2020-2025 | Odomzo, Blu-U |
| Regeneron Pharmaceuticals, INC. | $15,221.53 | 2025 | Libtayo |
| Biofrontera INC. | $9,741.84 | 2020-2025 | Bf-Rhodoled, Ameluz, Ameluz |
| E.R. Squibb & Sons, L.L.C. | $245.97 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $85.97 | 2019 | |
| Convatec INC. | $35.02 | 2025 | |
| Smith+Nephew, INC. | $27.07 | 2024 | Grafix Pl, Stravix |
| Organogenesis INC. | $24.26 | 2023 | Puraply |
| Dusa Pharmaceuticals, INC. | $15.75 | 2019 | |
| Misonix INC | $12.45 | 2021 | |
| Covidien Lp | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Moody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.